Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 19/20 | 0.58 |
| ▸ | GUCY1B1 | Q02153 | 19/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1791570 | 1.00 | GUCY1A1 (0.58) | GUCY1A1GUCY1B1KDM4EPOLBHPGD | |
| SCHEMBL1784657 | 0.93 | GUCY1A1 (0.56) | GUCY1A1GUCY1B1 | |
| SCHEMBL12603769 | 0.93 | GUCY1A1 (0.56) | GUCY1A1GUCY1B1 | |
| SCHEMBL1784660 | 0.93 | GUCY1A1 (0.56) | GUCY1A1GUCY1B1 | |
| SCHEMBL3034884 | 0.91 | GUCY1A1 (0.64) | GUCY1A1GUCY1B1 | |
| SCHEMBL20962998 | 0.87 | GUCY1A1 (0.55) | GUCY1A1GUCY1B1 | |
| SCHEMBL3996353 | 0.85 | GUCY1A1 (0.60) | GUCY1A1GUCY1B1KDM4EPOLBHPGD | |
| SCHEMBL3039805 | 0.85 | GUCY1A1 (0.60) | GUCY1A1GUCY1B1 | |
| SCHEMBL3998343 | 0.84 | GUCY1A1 (0.58) | GUCY1A1GUCY1B1KDM4EPOLBHPGD | |
| SCHEMBL3041028 | 0.83 | GUCY1A1 (0.61) | GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197551-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2016-12-28 | — | — | EP | disclosed |
| US-8455638-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A2, GUCY1A1 | GUCY1A1 3/4885GUCY1B1 1/4885KDM4E 1970/4885 |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | GUCY1A1 3/4885GUCY1B1 1/4885KDM4E 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.